好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Remote Monitoring of Motor, Speech, and Cognitive Function in Progressive Supranuclear Palsy
General Neurology
P10 - Poster Session 10 (11:45 AM-12:45 PM)
4-005

Develop and implement a multi-modal remote monitoring digital solution to assess motor, speech, and cognitive function in Progressive Supranuclear Palsy (PSP) patients.
PSP is a debilitating neurodegenerative disease that rapidly and profoundly impairs motor, speech and cognitive function. A multi-modal monitoring approach addressing multiple clinical domains can provide valuable insights into disease progression and may help develop targeted therapies.
Individuals diagnosed with PSP were enrolled and followed for 12 months. Clinical assessments including PSP Rating Scale (PSPRS) and MoCA were administered every three months for a total of 5 assessments. Digital psychomotor, speech and cognitive assessments were collected using the BioDigit Home tablet (BioSensics, Newton, MA, USA). Wearable sensors (PAMSys and LEGSys) were used for objective motor assessment of the Timed Up and Go test (TUG), 2-minute walk test (2MWT), and for continuous monitoring of physical activity and posture.
To date, 20 individuals diagnosed with PSP have been enrolled in the study and followed for 6-12 months. Correlations between PSPRS scores and sensor-derived measured of physical activity, such as cadence and stride duration, show moderate effect sizes. We also observed significant correlations between several parameters of digital speech and cognitive assessment scores compared to the relevant clinical scores (e.g., bulbar subdomain scores of PSPRS and MoCA).
Multi-modal remote monitoring shows promise in assessing PSP's clinical progression, offering insights into specific aspects of the disease, including motor, gait, and speech. We plan to create a digital PSP Rating Scale to quantitatively measure progression in each of these domains. These results will allow for remote capture of clinically relevant outcomes, improving access for patients with geographic constraints and physical disabilities who are currently unable to participate in clinical trials. Ultimately, our findings may help improve clinical care and therapy development in PSP.
Authors/Disclosures
Ram Kinker Mishra, PhD (Biosensics)
PRESENTER 		Dr. Mishra has received personal compensation for serving as an employee of BioSensics LLC.
Mansi Sharma (Massachusetts General Hospital) Miss Sharma has nothing to disclose.
AJ Hall (Johns Hopkins University) AJ Hall has nothing to disclose.
Jose Casado (BioSensics LLC) Jose Casado has received personal compensation for serving as an employee of Biosensics.
Adonay Nunes (Biosensics) Adonay Nunes has nothing to disclose.
Ashkan Vaziri, PhD (Biosensics LLC) Dr. Vaziri has received personal compensation for serving as an employee of Biosensics.
Alexander Pantelyat, MD, FAAN (Johns Hopkins University School of Medicine) Dr. Pantelyat has received personal compensation for serving as an employee of MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MedRhythms, Inc.. Dr. Pantelyat has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Kelly & Ignoffo Law Group. The institution of Dr. Pantelyat has received research support from NIH/NIA.
Anne Marie A. Wills, MD (MGH) Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant, a CVS/Caremark company. Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi/Genzyme. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Wills has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Parkinson's Foundation. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ono Pharmaceuticals. The institution of Dr. Wills has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Wills has received research support from Parkinson's Foundation. The institution of Dr. Wills has received research support from Biogen. The institution of Dr. Wills has received research support from Roche/Genentech. The institution of Dr. Wills has received research support from BioSensics.